445 related articles for article (PubMed ID: 11812782)
1. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
[TBL] [Abstract][Full Text] [Related]
2. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
3. Forcing nonamyloidogenic beta-synuclein to fibrillate.
Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
Biere AL; Wood SJ; Wypych J; Steavenson S; Jiang Y; Anafi D; Jacobsen FW; Jarosinski MA; Wu GM; Louis JC; Martin F; Narhi LO; Citron M
J Biol Chem; 2000 Nov; 275(44):34574-9. PubMed ID: 10942772
[TBL] [Abstract][Full Text] [Related]
5. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.
Uversky VN; Li J; Fink AL
J Biol Chem; 2001 Nov; 276(47):44284-96. PubMed ID: 11553618
[TBL] [Abstract][Full Text] [Related]
6. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
7. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
8. Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes.
Munishkina LA; Phelan C; Uversky VN; Fink AL
Biochemistry; 2003 Mar; 42(9):2720-30. PubMed ID: 12614167
[TBL] [Abstract][Full Text] [Related]
9. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
Ghee M; Melki R; Michot N; Mallet J
FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
[TBL] [Abstract][Full Text] [Related]
10. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation.
Munishkina LA; Henriques J; Uversky VN; Fink AL
Biochemistry; 2004 Mar; 43(11):3289-300. PubMed ID: 15023080
[TBL] [Abstract][Full Text] [Related]
11. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
Li J; Uversky VN; Fink AL
Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a partially folded intermediate in alpha-synuclein fibril formation.
Uversky VN; Li J; Fink AL
J Biol Chem; 2001 Apr; 276(14):10737-44. PubMed ID: 11152691
[TBL] [Abstract][Full Text] [Related]
13. Trimethylamine-N-oxide-induced folding of alpha-synuclein.
Uversky VN; Li J; Fink AL
FEBS Lett; 2001 Nov; 509(1):31-5. PubMed ID: 11734201
[TBL] [Abstract][Full Text] [Related]
14. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS.
Li J-; Henning Jensen P; Dahlström A
Neuroscience; 2002; 113(2):463-78. PubMed ID: 12127102
[TBL] [Abstract][Full Text] [Related]
15. Dependence of alpha-synuclein aggregate morphology on solution conditions.
Hoyer W; Antony T; Cherny D; Heim G; Jovin TM; Subramaniam V
J Mol Biol; 2002 Sep; 322(2):383-93. PubMed ID: 12217698
[TBL] [Abstract][Full Text] [Related]
16. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease.
Uversky VN; Li J; Fink AL
FEBS Lett; 2001 Jul; 500(3):105-8. PubMed ID: 11445065
[TBL] [Abstract][Full Text] [Related]
17. Engineered alpha-synuclein prevents wild type and familial Parkin variant fibril formation.
Sode K; Usuzaka E; Kobayashi N; Ochiai S
Biochem Biophys Res Commun; 2005 Sep; 335(2):432-6. PubMed ID: 16081040
[TBL] [Abstract][Full Text] [Related]
18. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle.
Uversky VN; Fink AL
FEBS Lett; 2002 Jul; 522(1-3):9-13. PubMed ID: 12095610
[TBL] [Abstract][Full Text] [Related]
19. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
Cohlberg JA; Li J; Uversky VN; Fink AL
Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
[TBL] [Abstract][Full Text] [Related]
20. Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein.
Hokenson MJ; Uversky VN; Goers J; Yamin G; Munishkina LA; Fink AL
Biochemistry; 2004 Apr; 43(15):4621-33. PubMed ID: 15078109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
